Cargando…
Impact of maintenance dose of eptifibatide in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention
BACKGROUND: ST-segment elevation myocardial infarction (STEMI) is usually caused by a rupture in the atherosclerotic plaque, followed by platelet aggregation which ultimately leads to acute coronary artery occlusion. So far, few studies have investigated the effect of maintenance dose of Eptifibatid...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105801/ https://www.ncbi.nlm.nih.gov/pubmed/37060533 http://dx.doi.org/10.1186/s43044-023-00355-4 |
_version_ | 1785026290441519104 |
---|---|
author | Jalalian, Rozita Bagheri, Babak Yazdani Charati, Jamshid Khalaghi, Shahrnaz Iranian, Mohammadreza Mohammadi, Mahsa |
author_facet | Jalalian, Rozita Bagheri, Babak Yazdani Charati, Jamshid Khalaghi, Shahrnaz Iranian, Mohammadreza Mohammadi, Mahsa |
author_sort | Jalalian, Rozita |
collection | PubMed |
description | BACKGROUND: ST-segment elevation myocardial infarction (STEMI) is usually caused by a rupture in the atherosclerotic plaque, followed by platelet aggregation which ultimately leads to acute coronary artery occlusion. So far, few studies have investigated the effect of maintenance dose of Eptifibatide (glycoprotein IIb/IIIa inhibitor) in STEMI patients who underwent primary percutaneous coronary intervention (PPCI). Therefore, in this study, we investigated the effect of maintenance dose of Eptifibatide in patients with STEMI who underwent PPCI. 264 patients who had acute chest pain suggestive of STEMI were entered in the study. All patients received the same dose of bolus dose of Eptifibatide in the cardiac catheterization laboratory. Then the patients were randomly divided into two groups, one group (n = 147) received a maintenance dose of intravenous Eptifibatide (infusion of 2 μg/kg/min) and the other group (n = 117) did not receive this treatment. Standard medical treatment of STEMI after PPCI was performed based on guidelines and the same in both groups. All patients were evaluated 1, 2, and 3 months after the start of treatment in terms of predicted outcomes. RESULTS: The occurrence of 3-month major adverse cardiovascular events (MACE) between the case and control groups did not have a statistically significant difference (28.6% versus 35.0%; P value: 0.286). Also, investigations showed that the rate of re-infarction (P value: 0.024) and target lesion revascularization (P value: 0.003) was significantly lower in the group that received Eptifibatide infusion. CONCLUSIONS: Eptifibatide maintenance dose infusion in patients who undergo PPCI in the context of STEMI, does not significantly reduce MACE, although it does significantly reduce re-infarction and target lesion revascularization. It also does not increase the risk of bleeding and cerebrovascular events. |
format | Online Article Text |
id | pubmed-10105801 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-101058012023-04-17 Impact of maintenance dose of eptifibatide in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention Jalalian, Rozita Bagheri, Babak Yazdani Charati, Jamshid Khalaghi, Shahrnaz Iranian, Mohammadreza Mohammadi, Mahsa Egypt Heart J Research BACKGROUND: ST-segment elevation myocardial infarction (STEMI) is usually caused by a rupture in the atherosclerotic plaque, followed by platelet aggregation which ultimately leads to acute coronary artery occlusion. So far, few studies have investigated the effect of maintenance dose of Eptifibatide (glycoprotein IIb/IIIa inhibitor) in STEMI patients who underwent primary percutaneous coronary intervention (PPCI). Therefore, in this study, we investigated the effect of maintenance dose of Eptifibatide in patients with STEMI who underwent PPCI. 264 patients who had acute chest pain suggestive of STEMI were entered in the study. All patients received the same dose of bolus dose of Eptifibatide in the cardiac catheterization laboratory. Then the patients were randomly divided into two groups, one group (n = 147) received a maintenance dose of intravenous Eptifibatide (infusion of 2 μg/kg/min) and the other group (n = 117) did not receive this treatment. Standard medical treatment of STEMI after PPCI was performed based on guidelines and the same in both groups. All patients were evaluated 1, 2, and 3 months after the start of treatment in terms of predicted outcomes. RESULTS: The occurrence of 3-month major adverse cardiovascular events (MACE) between the case and control groups did not have a statistically significant difference (28.6% versus 35.0%; P value: 0.286). Also, investigations showed that the rate of re-infarction (P value: 0.024) and target lesion revascularization (P value: 0.003) was significantly lower in the group that received Eptifibatide infusion. CONCLUSIONS: Eptifibatide maintenance dose infusion in patients who undergo PPCI in the context of STEMI, does not significantly reduce MACE, although it does significantly reduce re-infarction and target lesion revascularization. It also does not increase the risk of bleeding and cerebrovascular events. Springer Berlin Heidelberg 2023-04-15 /pmc/articles/PMC10105801/ /pubmed/37060533 http://dx.doi.org/10.1186/s43044-023-00355-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Jalalian, Rozita Bagheri, Babak Yazdani Charati, Jamshid Khalaghi, Shahrnaz Iranian, Mohammadreza Mohammadi, Mahsa Impact of maintenance dose of eptifibatide in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention |
title | Impact of maintenance dose of eptifibatide in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention |
title_full | Impact of maintenance dose of eptifibatide in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention |
title_fullStr | Impact of maintenance dose of eptifibatide in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention |
title_full_unstemmed | Impact of maintenance dose of eptifibatide in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention |
title_short | Impact of maintenance dose of eptifibatide in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention |
title_sort | impact of maintenance dose of eptifibatide in patients with st-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105801/ https://www.ncbi.nlm.nih.gov/pubmed/37060533 http://dx.doi.org/10.1186/s43044-023-00355-4 |
work_keys_str_mv | AT jalalianrozita impactofmaintenancedoseofeptifibatideinpatientswithstsegmentelevationmyocardialinfarctionwhounderwentprimarypercutaneouscoronaryintervention AT bagheribabak impactofmaintenancedoseofeptifibatideinpatientswithstsegmentelevationmyocardialinfarctionwhounderwentprimarypercutaneouscoronaryintervention AT yazdanicharatijamshid impactofmaintenancedoseofeptifibatideinpatientswithstsegmentelevationmyocardialinfarctionwhounderwentprimarypercutaneouscoronaryintervention AT khalaghishahrnaz impactofmaintenancedoseofeptifibatideinpatientswithstsegmentelevationmyocardialinfarctionwhounderwentprimarypercutaneouscoronaryintervention AT iranianmohammadreza impactofmaintenancedoseofeptifibatideinpatientswithstsegmentelevationmyocardialinfarctionwhounderwentprimarypercutaneouscoronaryintervention AT mohammadimahsa impactofmaintenancedoseofeptifibatideinpatientswithstsegmentelevationmyocardialinfarctionwhounderwentprimarypercutaneouscoronaryintervention |